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Abstract: Conventional in vitro human hepatic models for drug testing are based on the use of 
standard cell lines derived from hepatomas or primary human hepatocytes (PHHs). Limited 
availability, inter-donor functional variability and early phenotypic alterations of PHHs 
restrict their use; whilst standard cell lines such as HepG2 lack a substantial and variable set 
of liver-specific functions such as CYP450 activity. Alternatives include the HepG2-
derivative C3A cells selected as a more differentiated and metabolically active hepatic 
phenotype. Human HepaRG cells are an alternative organotypic co-culture model of 
hepatocytes and cholangiocytes reported to maintain in vivo-like liver-specific functions, 
including intact Phase 1-3 drug metabolism. In this study, we compared C3A and human 
HepaRG cells using phenotypic profiling, CYP450 activity and drug metabolism parameters 
to assess their value as hepatic models for pre-clinical drug testing or therapeutics. Compared 
with C3As, HepaRG co-cultures, exhibit a more organotypic phenotype, including evidence 
of hepatic polarity with strong expression of CYP3A4, the major isoform involved in the 
metabolism of over 60% of marketed drugs. Significantly greater CYP450 activity and 
expression of CYP1A2, CYP2E1 and CYP3A4 genes in HepaRG cells (comparable with that 
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of human liver tissue) was demonstrated. Moreover, HepaRG cells also preferentially 
expressed the hepatic integrin α5β1 – an important modulator of cell behaviour including 
growth and survival, differentiation and polarity. Drug metabolite profiling of phenacetin 
(CYP1A2) and testosterone (CYP3A4) using LC-MS/MS and HPLC, respectively, revealed 
HepaRGs had more intact (Phase 1-2) metabolism profile. Thus, HepaRG cells significantly 
outperform C3A cells for potential pharmaceutical and therapeutic applications. 
  
Withdrawal of licensed drugs from the market despite passing both pre-clinical in vitro and in 
vivo toxicity testing continues to be a significant problem. Development of improved in vitro 
human hepatic models for pre-clinical drug testing are required to more closely resemble the 
in vivo hepatic environment and minimize inter-species differences1. Hence, in vitro 
toxicological models based on human hepatic cell lines would provide more comparable and 
informative readout than animal models. In order to develop a physiologically-relevant, 
sustainable and reproducible in vitro culture system, the choice of a suitable cell line is 
critical. Human hepatoma-derived cell lines such as HepG2 and Huh7 are commonly used in 
early drug safety assessment2, but often fail to predict hepatotoxic drugs. The ideal cell model 
should maintain metabolic pathways such as key CYP450 enzyme activities, possess an intact 
drug transporter system (hepatic polarity) and be able to offer mechanistic insight into effects 
of drugs at both the cellular and molecular level. In addition, such culture systems should 
have a stable metabolic phenotype to further ensure reproducibility and flexibility of use. 
Primary human hepatocytes (PHHs) are the preferred in vitro model for many pharmaceutical 
and therapeutic approaches. However, limited availability, inter-donor functional and genetic 
variability and early phenotypic alterations of PHHs cultures restrict their application, such as 
repeat/ chronic toxicity studies, or availability for cell therapeutics. Integrity of PHHs used 
for modelling metabolic processes may be in question given the inherent phenotypic 
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instability of PHHs since upon isolation, the cells are in a state of pre-apoptotic stress with 
differences in stability of individual CYP450s in culture3. This represents a major challenge 
for pharma where standardization and development of more practical, sustainable, and stable 
physiologically-relevant alternatives are prerequisite for improving pre-clinical testing 
outcomes.  
Although hepatoblastoma-derived cancer cells, such as the HepG2 cell line are an 
inexpensive and convenient model, widely used in pre-clinical drug testing, they lack a 
substantial set of liver-specific functions, particularly, CYP450 activity4. The HepG2/C3A 
cell line (herein designated C3A cells) is a clonal derivative of the HepG2 cell line. C3A cells 
were selected as a more differentiated and metabolically active hepatic phenotype, compared 
with the parent HepG2 cell line5. 
Previously, we demonstrated enhancement of the C3A cell phenotype, including CYP3A4 
activity/albumin synthesis, by co-culture with human endothelial cells5, and through 
‘metabolic’ pre-conditioning6, whilst others have used tissue engineering approaches to 
augment C3A cell metabolism[7-8]. Forced transfection of HepG2 hepatic cell lines with 
CYP2E1-containing plasmids is also performed for highly specific applications, such as 
ethanol toxicity studies9. Notably, C3A and human HepaRG hepatic cell lines have been 
implemented as the biological component of bioartificial liver systems (BALs)10. Suggesting 
both cell types possess a sufficiently ‘organotypic’ phenotypic and functional properties to 
support patients with acute liver failure. However, it is not known whether conventional C3A 
cell monocultures are a practicable model for use in metabolic studies for pre-clinical drug 
testing or for clinical applications such as BALs11. Indeed, limited functionality, low CYP 
activity, or poor sustainability would represent significant barriers, for BAL application[12,13].  
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The human HepaRG hepatic cell line has emerged as a potential surrogate to PHHs for pre-
clinical hepatotoxicity assays14. HepaRGs are a unique (intrinsic), terminally-differentiated 
co-culture of hepatocyte- and cholangiocyte-like cells containing many functional and 
phenotypic similarities with PHH15. These cells were procured from a young adult female 
with hepatocarcinoma16. HepaRGs are a highly reproducible cell line, without the donor 
variability seen in PHHs, and as such ensure a consistent and phenotypically stable cell line, 
presenting a potentially more standardised model17. HepaRG cells retain some of the major 
CYP450 pathways and Phase II, enzymes - as well as production of glucose/glycogen and 
urea[15-17]. These cells also show functional polarity, a hallmark of in vivo hepatocyte 
organisation15, with intact Phase III drug transporters. These properties are generally not 
evident in ‘standard’ human hepatic cell lines monocultures. Given their potential for 
pharmaceutical applications and cell therapeutics including BALs, studies comparing such 
widely used human hepatic cell lines are surprisingly limited, whilst direct comparisons 
between C3A cells and HepaRG cells have not been previously reported. In this study, we 
aimed to compare phenotypic and metabolic parameters, including CYP450 activity and 
metabolism between HepG2/C3A and human HepaRG cells, to assess their value as suitable 
hepatic models for pre-clinical drug testing and therapeutics. 
 
Materials and Methods  
Cell Culture 
C3A cells (HepG2/C3A), derivative of HepG2: ATCC® CRL-10741™) were cultured on 
Corning plates in Minimum Essential Medium Eagle (MEME+; Sigma Aldrich) with 10% 
foetal bovine serum (FBS, Life Technologies, Paisley, UK) and 1% penicillin/streptomycin 
(Life Technologies).  The culture was kept at 37°C 5% CO2 until ~80% confluency. HepaRG 
cells (HRG116 terminally-differentiated cells, BioPredic international, Rennes, France) were 
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seeded (following the suppliers protocols) on Corning plates and cultured to confluence at 
37°C 5% CO2 for 7 days. 
Immunocytochemistry 
On culture day 8, cells were fixed in 4% paraformaldehyde (Sigma-Aldrich), permeabilized 
with 0.1% Triton X-100 in Tris Buffered Saline (TBS), then blocked with TBS containing 
5% Bovine Serum Albumin (BSA; Sigma-Aldrich) - before incubation with primary (rabbit) 
anti-human CYP3A4 antibody (AB1254, Chemicon, Millipore, Hertfordshire, UK) (1:800) 
and TRITC-conjugated Phalloidin (Sigma Aldrich) (1:100). Cells were then treated with 
appropriate secondary anti-rabbit antibody (Alexa Fluor® 488) prior to (nuclear) staining 
with DAPI (1:5000) for 5 min. Cell morphology was assessed under phase contrast and for 
immunocytofluorescent staining using an EVOS AUTO FL microscope (Life Technologies). 
Images were merged using ImageJ 1.47v (National Institute of Health, Bethesda, MD, USA). 
 
Biotransformation potential 
Cytochrome P450 enzyme activity 
Cells were treated for 24 hr with prototypical inducers 50µM omeprazole (CYP1A2) or 
rifampicin (CYP3A4), with or without addition of CYP450 isoform-specific specific 
inhibitors 25µM Fluvoxamine (CYP1A2) or Ketoconazole (CYP3A4), in MEME (C3As) or 
hepatocyte induction medium (HepaRGs). Cells were then washed twice with HBSS. 
Specific CYP450 enzyme activity was subsequently assessed using a non-lytic luminescence 
assay using specific kits for CYP1A2 and CYP3A4, following the manufacturer’s 
instructions (P450-Glo, Promega, Southampton, UK). Bioluminescent signals were detected 
with a GloMax-Multi+ Microplate Multimode Reader (Promega). Individual luminescent 
assay readings were background-corrected and normalized to cellular ATP content. 
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Phase 1 and 2 metabolism of Phenacetin and Testosterone 
In order to profile relative drug metabolism in each cell type, metabolites formed by CYP1A2 
or CYP3A4 hepatic metabolism were assessed following exposure to 50 μM phenacetin 
(CYP1A2), or testosterone (CYP3A4) for 2 hr at 37°C. Reactions were stopped on ice, cell 
supernatant (medium) samples stored at -80°C before analytical measurements using HPLC 
(testosterone) or LC-MS/MS (phenacetin). 
Phenacetin metabolism: Liquid chromatography-mass spectrometry  
Phenacetin metabolism was assessed using an ABI Applied Biosystems 5500 QTrap Mass 
spectrometer and AB Sciex software, Analyst 1.5.1; and LightSight software to identify 
metabolites. Methods are described in detail in Supplementary Information.  
 
Testosterone 
Relative turnover and metabolic breakdown of testosterone was assessed by HPLC-UV with 
absorbance at 254nm. Samples were enriched with an internal standard (20 µg/ml 11 α- 
hydroxyprogesterone in methanol) and extracted with dichloromethane before they were 
resuspended in 30% methanol and injected (25 uL) onto an Eclipse XD8-C18 3 µm 3 x 100 mm 
column (Agilent, Cheadle, UK). A series of calibration standards were prepared containing 6β, 
7α, 16α, 16β and 2α-hydroxytestosterone, plus internal standard. Androstenedione and 
testosterone were analysed at the start of each run at 0.25, 0.5, 1, 2.5, 5, 7.5 and 10 nmoles in 
30% methanol. 
 
Flow Cytometry 
Integrin expression of C3A cells was compared with HepaRG cells, including the progenitor 
HepaRG101 cell line - and following differentiation to terminally-differentiated HepaRG116 
cells. This allows assessment of integrin expression in C3A cells, known to express foetal 
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markers (eg alpha-fetoprotein), with both the HepaRG101 (hepatoblast-like) progenitors, and 
their derivatives (HepaRG116), as comparators. To assess expression of integrins, single cell 
suspensions were enzymatically recovered using xeno-free Tryple (Life Technologies) – 
which protects cellular surface proteins, washed and resuspended in FACS-PBS (PBS 
containing 0.1% BSA and 0.1% sodium azide), for simultaneous staining with a panel of 
fluorochrome-labeled integrin antibodies: CD29-BV510, CD49f-BV451, CD49d-FITC, 
CD49c-PE, CD49a-APC-Vio770, CD49b-PE-Vio770, CD49e-APC, (all Miltenyi Biotec). 
Cells were incubated with antibodies at 4ºC for 20 min., washed twice and re-suspended in 
FACS-PBS. Unstained cells were included as controls, whilst dead cells and debris were 
excluded from the analysis based on scatter characteristics. Data for at least 10,000 live 
events per sample were acquired using a MACSQuant Analyzer (Miltenyi Biotec) and was 
analysed using FlowJo version 9.6.7 software (FlowJo LLC). Data are presented as 
percentage positive staining. 
 
Statistical Analysis 
All experiments were performed with three to eight technical replicates from a minimum of 
three independent biological experiments. Results are presented as mean ± standard error of 
the mean (SEM), and individual groups were (generally) compared with a two-tailed 
unpaired Student t-test to test significance as indicated. A p-value lower than 0.05 was 
considered statistically significant. 
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Results  
Phenotypic profiling of HepaRG and HepG2/C3A cells 
HepaRG cells formed terminally-differentiated in vivo-like hepatic cords and cholangiocyte-
like cells (fig. 1a) with functional polarity, as evidenced by punctate staining of F-actin bands 
indicative of bile-canalicular structures [phalloidin-staning, fig. 1c]; these could also be 
observed in C3A cells (fig. 1d), although with less pronounced staining. In contrast, high 
CYP3A4 protein expression (fig. 1c; green-staining) with strong expression of CYP2E1, 
CYP1A2 and CYP3A4 genes, was evident only in HepaRGs; indicative of high metabolic 
competence for drug metabolism (fig. 1e). 
 
Biotransformation potential 
CYP450 enzyme activity and specificity 
HepaRG CYP1A2 (fig. 2a) and CYP3A4 (fig. 2c) activity was significantly higher than that 
measured in HepG2/C3A cells [grey bars; p<0.0001]. In fact, relative luminescence measured 
in HepG2/C3A cells was at levels of blank controls. Specificity of CYP450 isoform induction 
was confirmed with the specific inhibitors [chequered grey bars]: Fluvoxamine (CYP1A2) 
and Ketoconazole (CYP3A4). 
 
Phase 1 and 2 metabolism of Phenacetin and Testosterone 
To further investigate the extent of CYP1A2 and 3A4 metabolic activity in each cell type, 
phenacetin (CYP1A2) and testosterone (CYP3A4) metabolism were used to assess metabolic 
competency. Compound turnover, and ratio of analyte to metabolite was assessed using 
LC:MS/MS (phenacetin) and HPLC (testosterone). Compared with C3A cells, HepaRG cells 
showed significantly higher turnover of phenacetin (28.5±4.4% versus 11.7±0.6%; p<0.01) 
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and testosterone (56.5±7.6% versus 2.0±0.2%; p<0.001, respectively), with a wider spectrum 
and more refined metabolic breakdown of phenacetin and testosterone in HepaRG cells. 
 
Phenacetin 
HepaRG cells yielded a higher turnover of phenacetin and gave a clear yield ratio of analyte 
to metabolite via end-point analysis (fig. 3a). We were able to characterize de-demethylation 
of our substrate, phenacetin, by observing significant mono- and tridemethylation of the 
parent metabolite into paracetamol (fig. 3b-d). In addition, characteristic secondary 
metabolites of sulfonation and glucoronidation were detected (data not shown). Such broad-
spectrum metabolism is not seen in C3A cells, where no secondary metabolites were 
detected.  
 
Testosterone 
Given each compound has its own unique absorbance, the chromatographic elution time of 
testosterone was compared in in vitro samples to that of known calibration standards, and 
HPLC-UV absorbance was assessed using a photodiode array detector. In contrast with 
C3As, HepaRG cells metabolised >50% of (total) testosterone – producing a major 
metabolite (6-β-hydroxy-testosterone), as well as a panel of other secondary metabolites (fig. 
4a) whilst C3A cells only showed presence of relatively minor metabolites, with low turnover 
of the parent compound (fig. 4b). Using HPLC were also able to measure the relative 
turnover of testosterone by hydroxylation (see fig. 3d) cells, while no trace of this metabolite 
is present in C3A cells.   
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Flow cytometric integrin expression in HepaRG and C3A cells  
Expression of integrins CD49a-f (α sub-units 1-6) and CD29 (β1 sub-unit) by C3A, 
HepaRG101 and HepaRG116 cells is shown in fig. 5. C3A cells expressed CD49a, CD49b, 
CD49f and CD29 but showed no staining for CD49c-e. The immature/undifferentiated 
hepatoblast-like cell line HepaRG101, showed a comparable phenotype, expressing CD49a, 
CD49b, CD49f, although the frequency and level of expression of CD49f was lower than 
seen for C3A.  In addition, HepaRG101 cells expressed CD49e, which was absent from C3A 
cells. HepaRG116 differentiated cells show hepatocyte, biliary and epithelial 
morphologically (fig. 5).  
 
Discussion 
Appropriate in vitro human models are urgently required to help reduce high drug attrition 
rates by detecting toxicity earlier and improving predictive outcomes, which may help reduce 
the reliance on subsequent animal testing in drug development. We compared two candidate 
human hepatic cell lines, HepaRG and C3A cells and demonstrated differential organotypic 
properties. Only HepaRG cells retain differentiated morphological, phenotypic and 
augmented functional features for context-specific applications such as in early-phase drug 
discovery and development, or BAL use. HepaRG cells may represent a more 
physiologically-relevant pre-clinical platform for CYP450 activation/ inhibition studies, 
safety pharmacology, as well as drug-drug interaction studies. 
Comparative assessment through characterization and validation of functional and phenotypic 
properties of candidate human hepatic cells, for a defined operational task, are not widely 
reported18. Compared with C3As, HepaRG co-cultures, exhibit a more organotypic 
phenotype, including evidence of hepatic polarity with strong expression of CYP3A4 (fig. 1), 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
the major isoform involved in the metabolism of over 60% of marketed drugs[12-13]
. 
Similarly, 
greater expression of CYP1A2, CYP2E1 and CYP3A4 genes in HepaRG cells, compared 
with C3As, is comparable with that of human liver biopsies, whilst HepG2 have also been 
shown to express very low CYP450 levels16. 
Analytical techniques including LC-MS/MS and flow cytometry allow candidate in vitro 
models to be interrogated for cell type-specific markers and drug reactive metabolite 
formation – allowing intrinsic (predictive) drug clearance rates to be calculated. Both 
turnover and the profile of HepaRG phenacetin and testosterone metabolites, is significantly 
broader compared with C3As (fig. 3-4), suggesting their usefulness in predictive drug testing. 
Moreover, LC-MS/MS profiling of phenacetin showed that only HepaRG cells catalyzed a 
range of complex phase 1 (oxidation, mono-demethylation and tri-demethylation) and phase 
2 (sulfonation and glucuronidation) reactions (see fig. 3b). 
Many in vitro drug testing assays use HepG2 cells, whilst the HepG2 derivative [19-20], C3A 
cells, have been utilized in tissue engineering and cell therapeutic applications, such as the 
extracorporeal liver assist device (ELAD) system. Although the ELAD system failed to meet 
expectations in clinical trials21. It is well known that detoxification capacity and mixed 
function oxidase activity is very poor22, in HepG2 cells, which require manipulation to 
stimulate CYP450 activity such as transfection23, whilst metabolic preconditioning6 can 
enhance functional suitability for BALs, drug safety or pharmacological experiments.  
Although useful in proliferation assays, further reported disadvantages of HepG2 cells, which 
we show in the present study, include lack of specific liver function (CYP450 activity/ 
metabolism) that potentially miss significant toxic effects of candidate compounds under 
investigation.  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
C3A cells are, however, a useful model for context-specific applications including predictive 
modelling of hepatotoxicants24, metabolomics and tissue engineering approaches including 
3D-spheroid formation7 and in microfluidics devices8, which improved phenotype and 
functionality. This is equally true of HepaRG cells which have been utilized in clinical 
applications such as BALs, hepatitis research and drug-induced liver injury (DILI)[15-16].  
 
Our study supports preferential usage of HepaRG over C3A cells in such applications  [12, 
13,]due to their reproducibility and stability (>28 days) in culture, coupled with a significantly 
greater array of gene and enzymatic mixed function oxidases (fig. 2). In agreement, other 
reports show these cells exhibit Phase I-III metabolism25. Indeed, Gerets et al.26 compared 
HepG2, HepaRG and PHHs assessing gene expression and employing real-time impedence 
biosensing with various CYP450 assays containing prototypical inducers. They found 
HepaRG cells to be the most inducible model, and metabolically more closely related to 
PHHs than HepG2. When comparing gene expression of Phase I, II and III mRNA between 
HepG2, HepaRG and PHH cells, they also found that HepG2 cells expressed the lowest 
mRNA values for almost every gene tested22. Altogether, these studies suggest HepaRG may 
be a useful surrogate to PHHs.  
We performed flow cytometric analysis to assess and compare the expression profile of cell 
surface integrin receptors. Integrin-mediated cell adhesion sites link the actin cytoskeleton 
with the extracellular matrix, and are important modulators of cell behaviour including 
growth and survival, differentiation and polarity27. Expression profiling reveals that 
HepaRG116 differentiated cells show markers associated with hepatocyte, biliary and 
epithelial morphologically (fig. 5). In contrast with C3A, which was derived from a 
hepatocellular carcinoma patient, the non-tumourigenic HepaRG cells, notably express the 
most abundant hepatocyte integrin α5 (the fibronectin receptor, α5β1), important in 
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development and cell differentiation processes. Therefore, HepaRG cells may represent a 
valuable model to study hepatic cell-cell/ cell-matrix interactions. 
Given that hepatic clearance of drugs depends on the activity of transport proteins located on 
the bile canalicular membranes, the unique properties of HepaRG polarity (Fig. 1), may 
permit focused approaches for cholestatic drug-based DILI studies as well as drug-drug 
interactions; a significant bottleneck in the drug development pipeline15. This, together with 
the broad hepatic functionality of the HepaRG in vitro co-culture system, also offers an 
opportunity to establish robust ‘disease-in-a-dish’ models and offer insight into the 
interaction between hepatocytes and cholangiocytes, a main feature of in vivo hepatic 
organisation. 
 
One disadvantage of the HepaRG cells is currently their cost when compared with the 
widely-available HepG2/C3A cells, which can be propagated through multiple passages. This 
is perhaps offset to some degree, by the stability of the HepaRG cells for a variety of time-
sensitive experiments such as: acute, chronic or repeat-dose hepatotoxicity studies; over 4 
weeks, so enabling a larger number of experiments with less variability and more stability. 
 
In conclusion, our comparative study supports human HepaRG cells as a more pertinent 
organotypic in vitro human model, compared with C3A cells, which may permit more 
predictive pre-clinical screening of drugs and could potentially reduce drug attrition, DILI 
and animal testing, leading to lower drug development costs. Defining physiological 
properties of such hepatic models, may inform future human liver tissue modelling strategies 
for a variety of pharmaceutical and therapeutic applications. 
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Figures 1-5: Legends 
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C3As form a confluent monolayer of hepatocyte-like cells, with less prominent bile 
canaliculi/ refractile borders (B). (C) HepaRG cells exhibit a highly differentiated phenotype 
(culture day 8), including: Tri-colour fluorescent-staining revealed extensive hepatic 
CYP3A4 enzyme activity (green); punctate staining of F-actin bands, indicative of bile-
canalicular structures [red phalloidin-staining, green arrows]; with in vivo-like hepatic cords 
and cholangiocyte-like cell ‘voids’. In contrast, in C3A cells CYP3A4 enzyme activity is 
undetected (D), with low CYP450 gene expression/metabolic competence in comparison with 
high CYP2E1, CYP1A2 and CYP3A4 gene expression in HepaRG cells, following end-point 
PCR (E). 
Fig. 2 Metabolic profiling of human hepatic HepaRG compared with C3A cells.  
Measurement of prototypical inducers Omeprazole (CYP1A2) and Rifampicin (CYP3A4) in 
both HepaRG and C3A cells (A, C).  Fluvoxamine, a highly-specific inhibitor of CYP1A2 
and ketoconazole, a highly-specific inhibitor of CYP3A4, were used to demonstrate 
specificity. Relative metabolic turnover (ie. of total drug added to culture medium) of 
phenacetin (B) and testosterone (D). Results are presented as mean ± SEM, and individual 
groups were compared with a two-tailed, unpaired Student t-test to test significance as 
indicated. A p-value <0.05 was considered statistically significant. P<0.01**; p<0.001*** 
 
Fig. 3 Representative chromatograph extracted from Light Sight software:  
Peak of parent compound phenacetin at its unique 180.0 m/z ratio (A). Schematic diagram 
showing Phase I and Phase II metabolism of Phenacetin: Phase 1 (De-demethylation) of 
phenacetin to paracetamol (acetaminophen), and phase 2 secondary metabolites of 
acetaminophen via the processes of glucoronidation, sulfonation and N-hydroxylation (B). 
LC-MS chromatograms: Representative chromatograms of mono- di- and tri-demethylation 
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of HepaRG cells following challenge with Phenacetin. The parent compound phenacetin is 
shown at 180 m/z, mono-demethylation shown at 168 m/z, Di-demethylation 152 m/z, and 
tri-demethylation 138 m/z (C). D: Comparison of mean % turnover of demethylation 
(comparing mean % of mono- di- and tri-demethylation) between HepaRG and C3A cells. 
Fig. 4 Drug metabolite profiling of testosterone (CYP3A4) using HPLC 
Metabolism of testosterone in HepaRG cells on culture day 8 (A), showed a significant level 
of the major secondary metabolite 6-Beta-hydroxytestosterone and a wider range of 
secondary metabolites compared with in C3A cells (B). 
Fig. 5 Flow cytometry profiling of integrin expression in HepaRG and C3A cells  
Flow cytometry histograms comparing integrin expression (CD49a-f: α1-α6) and CD29 
(integrin β1) between C3A, HepaRG101 and HepaRG116 cell lines (dark lines); and isotype 
controls (grey lines). CD49d was not expressed by any of the 3 lines. The expression of 
CD49a, CD49b and CD29, was comparable between all 3 cell lines, though a proportion of 
HepaRG116 cells had down-regulated expression of these. Whereas expression of CD49e by 
HepaRG101 cells was maintained on HepaRG116 cells but absent from C3A cells. This was 
also true for expression of CD49c, except that there was some down-regulation of expression 
by HepaRG116 cells. Conversely C3A expressed CD49f, while it was absent or low on 
HepaRG101 and 116 cells. 
